TIMP3 median levels were negatively correlated with ascites in ovarian cancer patients qualified for neoadjuvant chemotherapy (r = 0.682, p = 0.02) and for primary surgery (r = 0.711. This evidence concerns the gene TIMP3 and ovarian carcinoma.